Products for Research Use Only

Binimetinib (Standard)

CAT: 0804-HY-15202R-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15202R-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Binimetinib (Standard) is the analytical standard of Binimetinib. This product is intended for research and analytical applications. Binimetinib (MEK162) is an oral and selective MEK1/2 inhibitor. Binimetinib (MEK162) inhibits MEK with an IC50 of 12 nM.
CAS Number
606143-89-9
Product Name Alternative
MEK162 (Standard) ; ARRY-162 (Standard) ; ARRY-438162 (Standard)
UNSPSC
12352005
Hazard Statement
H411
Target
Autophagy; MEK; Reference Standards
Type
Reference Standards
Related Pathways
Autophagy; MAPK/ERK Pathway; Others
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/binimetinib-standard.html
Smiles
BrC1=CC=C(C(F)=C1)NC2=C(C3=C(C=C2C(NOCCO)=O)N(C=N3)C)F
Molecular Formula
C17H15BrF2N4O3
Molecular Weight
441.23
Precautions
P273-P391-P501
References & Citations
[1]J Pheneger, et al. 2006, ACR Annual Scientific Meeting. Abst 794.|[2]Serra V, et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest, 2013, 123 (6), 2551-2563.|[3]Kiessling MK, et al. Mutant HRAS as novel target for MEK and mTOR inhibitors. Oncotarget. 2015 Dec 8;6 (39) :42183-96.|[4]Cheng H, et al. PIK3CA (H1047R) - and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene. 2016 Jun 9;35 (23) :2961-70.|[5]Seip K, et al. Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. Oncotarget. 2016 Apr 12;7 (15) :19997-20015.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards